Grabowski, Henry G.; Ridley, David B.; Schulman, Kevin A. - In: Managerial and Decision Economics 28 (2007) 4-5, pp. 439-451
Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologics can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemical...
